The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...

WILMINGTON, Del.--(BUSINESS WIRE)-- ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...

Ultomiris (ravulizumab-cwvz) is a prescription drug approved to treat certain rare inflammatory conditions. Ultomiris comes as a liquid solution for intravenous (IV) infusion, which is given by a ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. Next up, the complement inhibitor—which AZ inherited in ...

Ultomiris (ravulizumab-cwvz) is a brand-name injection that’s prescribed for certain rare diseases. As with other drugs, Ultomiris can cause side effects, such as upper respiratory tract infection and ...

The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...